Sub menu

 
 

FOI disclosure log

The Freedom of Information (FOI) disclosure log shows information which has been released in response to FOI requests.

Last updated

About the TGA Freedom of Information (FOI) disclosure log

The Department of Health and Aged Care, of which the TGA is a part, is required by section 11C of the Freedom of Information Act 1982 (the FOI Act) to disclose access decisions through a disclosure log on its website. The disclosure log provides access to information which has been released in response to an FOI request. However, personal information and information about the business, commercial, financial or professional affairs of a person is deleted from the documents if publication of that information would be unreasonable.

The documents released by the TGA under section 11C of the FOI Act have been made available on this site in Portable Document Format (PDF). They are available for downloading and printing. If you require access to the documents in an alternative format please contact the FOI Coordinator by emailing tga.foi@health.gov.au or calling the TGA on 1800 020 653 or 02 6289 4630.

For information on what’s involved when you request information from us and what's covered under the FOI Act, go to Freedom of information.

For documents released under the FOI Act by the Australian Government Department of Health and Aged Care, please visit the Department of Health's FOI disclosure log.

Our Freedom of Information (FOI) disclosure log

Date of releaseFOI numberDocuments
28 August 2024FOI 5169

Documents related to the risk of kidney injury/disease or gastric cancer as a result of the usage of proton pump inhibitors 

22 August 2024FOI 5308

Special Access Scheme Category A and B applications granted for unregistered antimicrobials from January 2017 to December 2023

21 August 2024FOI 5171

Delegate’s Overview for Lexapro

16 August 2024FOI 5316

Authorised prescriber approvals for Psilocybin and MDMA from 1 July 2023 to 30 June 2024

16 August 2024FOI 5049

Non-clinical evaluation report for pregabalin in Lyrica

15 August 2024FOI 5107

Emails and notifications received by the TGA containing "Relx", "QuitRX" and "Quitmed"

14 August 2024FOI 5255

Data relating to Authorised Prescriber and Special Access Scheme pathways for medicinal cannabis

5 August 2024FOI 5224

List of all new chemical and biological entities approved by the TGA

2 August 2024FOI 1890

Safety Study Test for the approval and registration of the first Gardasil vaccine.

1 August 2024FOI 5170

Briefing documents prepared by the TGA for the Minister for Health and Aged Care regarding safety issues associated with antidepressants, antipsychotics, benzodiazepines and z-drugs

26 July 2024FOI 5082

Documents relating to COVID-19 vaccine safety signal investigation processes

Please note: Product Information (PI) documents, published on the TGA website, are the most up-to-date reference for adverse events associated with individual COVID-19 vaccines products. The following document may refer to statistical signals that were not confirmed for further review, that were not found to be clinically meaningful, or that were unable to be validated with population-evidence sufficient to confirm an association. Internal TGA Standard Operating Procedures (SOP) and Work Instructions (WI) are designed for use by persons who have undertaken formal TGA induction and on-the-job training. It would be inappropriate for these documents to be utilised as written by someone who is not orientated to the science of pharmacovigilance and the work of the organisation.

24 July 2024FOI 5137

Consumer Medicine Information (CMI) and Product Information (PI) documents for Loxalate, Lexapro, Chemmart Brand Escitalopram, Escitalopram

18 July 2024FOI 5046

Documents relating to the assessment and approval of Nirsevimab (Beyfortus)

15 July 2024FOI 5201

Special Access Scheme and Authorised Prescriber data for [18F]Fluorodeoxyglucose (FDG) PET scans performed for brain cancer for the period 1 January 2018 to 1 June 2024

12 July 2024FOI 5192

Confirmation of cancellation and date of cancellation for Natrelle Saline-Filled Breast Implants, including styles SRL, SRF, SRM and SRX and Natrelle Silicone-Filled Textured Breast Implants, including styles SRL, SRF, SRM and SRX

1 Jul 2023 to 30 Jun 2024Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2023 - Jun 2024
1 Jul 2022 to 30 Jun 2023Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2022 to Jun 2023
1 Jul 2021 to 30 Jun 2022Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2021 to Jun 2022
1 Jul 2020 to 30 Jun 2021Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2020 to Jun 2021
1 Jul 2019 to 30 Jun 2020Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2019 to Jun 2020
1 Jul 2018 to 30 Jun 2019Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2018 to Jun 2019
1 Jul 2017 to 30 Jun 2018Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2017 to Jun 2018
1 Jul 2016 to 30 Jun 2017Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2016 to Jun 2017
1 Jul 2015 to 30 Jun 2016Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2015 to Jun 2016
1 Jul 2014 to 30 Jun 2015Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2014 to Jun 2015
1 Jul 2013 to 30 Jun 2014Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2013 to Jun 2014
1 Jul 2012 to 30 Jun 2013Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2012 to Jun 2013
1 Jul 2011 to 30 Jun 2012Documents released under Section 11C of the Freedom of Information Act 1982, Jul 2011 to Jun 2012

Page history

Help us improve the Therapeutic Goods Administration site